Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
AG, annum, assignment, assumed, bear, began, Bioscience, cardiovascular, central, concurrently, disposal, eleven, EPO, European, expand, facility, Fiorinal, Guarantee, hand, headache, hereof, incorporate, infringement, intellectual, key, lead, Maichle, marketplace, OTCQX, patent, percent, promissory, property, Regulation, relevant, relief, summary, TBUFF, thirteen, Trademark, USPTO, Viskazide, Visken, William
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 First Amendment to Credit Agreement
- 10.2 Warrant, Dated October 1, 2014, Issued to SWK Funding LLC In Connection with the First Amendment to the Credit Agreement and Guarantee
- 10.3 Intellectual Property Security Agreement, Dated October 1, 2014
- 10.4 Warrant Indenture, Dated July 15, 2014, Between Tribute Pharmaceuticals Canada Inc. and Equity Financial Trust Company.
- 10.5 Form of Broker Warrant, Dated July 15, 2014, Issued to the Underwriters In the Financing That Closed on July 15, 2014.
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
Related press release
SLRXF similar filings
Filing view
External links
EXHIBIT 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED
PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002)
I, Scott Langille, Chief Financial Officer, of Tribute Pharmaceuticals Canada Inc. (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. | The Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2014 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and, |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: November 10, 2014
/s/ Scott Langille | |
Scott Langille | |
Chief Financial Officer |